Motilal Oswal has initiated coverage on Sagility with a buy-equivalent rating and a target price of ₹57. The brokerage cites strong Q1 FY27 performance where revenue and profits topped estimates. Future growth expectations are driven by potential new client wins and cross-selling, though investors should track execution and integration of recent acquisitions.
Detailed Coverage
Motilal Oswal has initiated coverage on Sagility India, the healthcare-focused business process management company, with a target price of ₹57 per share. This move follows the company's recent financial results for the first quarter of fiscal year 2027, which exceeded market expectations.
Q1 FY27 Financial Highlights
In the June 2026 quarter, Sagility reported revenue of ₹19,635 million. This reflects a 27.6% increase compared to the same period last year in rupee terms. On a constant currency basis, which removes the impact of exchange rate fluctuations, revenue grew by 15.2%. The company’s operating profit, or EBITDA, reached ₹4,382 million, slightly higher than anticipated. The operating margin stood at 22.3%, remaining consistent with market expectations of 22.4%. Additionally, the company reported a net profit of ₹2,168 million, which was marginally above the forecast of ₹2,140 million.
Growth Strategy and Outlook
The brokerage’s positive outlook is based on a projected compounded annual growth rate of 19% for revenue, 19% for EBITDA, and 23% for net profit between fiscal years 2026 and 2028. This growth trajectory is expected to be supported by the company’s ability to attract new healthcare clients and increase the sales of additional services to its existing customers. A key component of the growth plan involves the successful integration of recent acquisitions, which management aims to use to build better business synergies. The target price of ₹57 is calculated based on a valuation of 19 times the expected earnings per share for the fiscal year 2028.
Investor Context and Monitorables
While the brokerage report highlights strong organic growth, investors often look beyond top-line numbers. For Sagility, a business primarily focused on the US healthcare payer and provider market, success depends on maintaining service quality and navigating the complex US healthcare regulatory landscape. As the company continues to spend on expansion and acquisitions, monitoring the return on these investments remains important. Investors may also want to track the company's ability to maintain its margin levels as it competes for larger contracts in a competitive healthcare BPM sector. The integration process of its recent acquisitions and the speed at which new client revenue begins to contribute to the bottom line will be important indicators of the company's operational health in the coming quarters.